for Journals by Title or ISSN
for Articles by Keywords
help
  Subjects -> MEDICAL SCIENCES (Total: 7268 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (198 journals)
    - ANAESTHESIOLOGY (104 journals)
    - CARDIOVASCULAR DISEASES (306 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (21 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (199 journals)
    - DENTISTRY (247 journals)
    - DERMATOLOGY AND VENEREOLOGY (147 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (107 journals)
    - ENDOCRINOLOGY (137 journals)
    - FORENSIC SCIENCES (33 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (162 journals)
    - GERONTOLOGY AND GERIATRICS (115 journals)
    - HEMATOLOGY (141 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (134 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (87 journals)
    - MEDICAL GENETICS (59 journals)
    - MEDICAL SCIENCES (1810 journals)
    - NURSES AND NURSING (294 journals)
    - OBSTETRICS AND GYNECOLOGY (173 journals)
    - ONCOLOGY (351 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (122 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (146 journals)
    - OTORHINOLARYNGOLOGY (72 journals)
    - PATHOLOGY (97 journals)
    - PEDIATRICS (241 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (138 journals)
    - PSYCHIATRY AND NEUROLOGY (734 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (180 journals)
    - RESPIRATORY DISEASES (90 journals)
    - RHEUMATOLOGY (63 journals)
    - SPORTS MEDICINE (68 journals)
    - SURGERY (353 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (135 journals)

GASTROENTEROLOGY AND HEPATOLOGY (162 journals)                     

Showing 1 - 162 of 162 Journals sorted alphabetically
Abdominal Imaging     Hybrid Journal   (Followers: 14)
Acta Endoscopica     Hybrid Journal   (Followers: 1)
Acta Gastroenterologica Latinoamericana     Open Access   (Followers: 3)
Actualités Odonto-Stomatologiques     Open Access   (Followers: 4)
Advances in Diabetes and Metabolism     Open Access   (Followers: 15)
Advances in Digestive Medicine     Open Access   (Followers: 6)
AJP Gastrointestinal and Liver Physiology     Full-text available via subscription   (Followers: 5)
Akademik Gastroenteroloji Dergisi     Open Access  
Alimentary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 33)
Alimentary Pharmacology & Therapeutics Symposium Series     Hybrid Journal   (Followers: 3)
American Journal of Gastroenterology Supplements     Full-text available via subscription   (Followers: 8)
American Journal of Gastroenterology, The     Hybrid Journal   (Followers: 126)
Annals of Gastroenterology     Open Access  
Arab Journal of Gastroenterology     Full-text available via subscription   (Followers: 3)
Arquivos de Gastroenterologia     Open Access   (Followers: 1)
Australian and New Zealand Continence Journal     Full-text available via subscription   (Followers: 3)
Avances en Odontoestomatologia     Open Access   (Followers: 1)
Best Practice & Research Clinical Gastroenterology     Full-text available via subscription   (Followers: 10)
BMC Gastroenterology     Open Access   (Followers: 15)
BMJ Open Diabetes Research & Care     Open Access   (Followers: 21)
BMJ Open Gastroenterology     Open Access   (Followers: 6)
Canadian Journal of Gastroenterology & Hepatology     Open Access   (Followers: 4)
Case Reports in Gastroenterology     Open Access   (Followers: 4)
Case Reports in Gastrointestinal Medicine     Open Access   (Followers: 3)
Case Reports in Hepatology     Open Access   (Followers: 1)
Cellular and Molecular Gastroenterology and Hepatology     Open Access   (Followers: 3)
Clinical and Experimental Gastroenterology     Open Access   (Followers: 3)
Clinical and Molecular Hepatology     Open Access   (Followers: 2)
Clinical and Translational Gastroenterology     Open Access   (Followers: 3)
Clinical Diabetes     Full-text available via subscription   (Followers: 37)
Clinical Gastroenterology and Hepatology     Hybrid Journal   (Followers: 28)
Clinical Journal of Gastroenterology     Hybrid Journal   (Followers: 12)
Clinical Medicine Insights : Gastroenterology     Open Access   (Followers: 5)
Clinics and Research in Hepatology and Gastroenterology     Hybrid Journal   (Followers: 8)
Clinics in Liver Disease     Full-text available via subscription   (Followers: 11)
Colon & Rectum     Hybrid Journal   (Followers: 4)
coloproctology     Hybrid Journal   (Followers: 2)
Colorectal Disease     Hybrid Journal   (Followers: 13)
Comparative Hepatology     Open Access   (Followers: 3)
Current Bladder Dysfunction Reports     Hybrid Journal  
Current Colorectal Cancer Reports     Hybrid Journal   (Followers: 3)
Current Diabetes Reports     Hybrid Journal   (Followers: 24)
Current Gastroenterology Reports     Hybrid Journal   (Followers: 4)
Current Hepatitis Reports     Hybrid Journal   (Followers: 7)
Current Opinion in Gastroenterology     Hybrid Journal   (Followers: 11)
Current Treatment Options in Gastroenterology     Hybrid Journal   (Followers: 6)
Der Gastroenterologe     Hybrid Journal  
Diabetes     Full-text available via subscription   (Followers: 406)
Diabetes Spectrum     Full-text available via subscription   (Followers: 13)
Diagnostic and Therapeutic Endoscopy     Open Access  
Dialysis & Transplantation     Hybrid Journal   (Followers: 6)
Digestion     Full-text available via subscription   (Followers: 5)
Digestive and Liver Disease     Hybrid Journal   (Followers: 15)
Digestive and Liver Disease Supplements     Full-text available via subscription   (Followers: 6)
Digestive Disease Interventions     Hybrid Journal  
Digestive Diseases     Full-text available via subscription   (Followers: 18)
Digestive Diseases and Sciences     Hybrid Journal   (Followers: 5)
Digestive Endoscopy     Hybrid Journal   (Followers: 2)
Diseases of the Colon & Rectum     Full-text available via subscription   (Followers: 28)
Diseases of the Esophagus     Hybrid Journal   (Followers: 1)
Dysphagia     Hybrid Journal   (Followers: 129)
Endoscopia     Open Access  
Endoscopy     Hybrid Journal   (Followers: 11)
Endoscopy International Open     Open Access  
Endoskopie heute     Hybrid Journal   (Followers: 1)
Esophagus     Hybrid Journal  
European Journal of Gastroenterology & Hepatology     Hybrid Journal   (Followers: 18)
Evidence-Based Gastroenterology     Full-text available via subscription   (Followers: 5)
Expert Review of Gastroenterology and Hepatology     Full-text available via subscription   (Followers: 8)
Frontline Gastroenterology     Full-text available via subscription   (Followers: 3)
Gastric Cancer     Hybrid Journal   (Followers: 1)
Gastroenterologia Kliniczna. Postępy i Standardy     Open Access  
Gastroenterología y Hepatología     Full-text available via subscription  
Gastroenterología y Hepatología (English Edition)     Hybrid Journal  
Gastroenterología y Hepatología Continuada     Full-text available via subscription  
Gastroenterologie up2date     Hybrid Journal   (Followers: 2)
Gastroenterology     Hybrid Journal   (Followers: 156)
Gastroenterology and Hepatology from bed to bench     Open Access   (Followers: 5)
Gastroenterology Clinics of North America     Full-text available via subscription   (Followers: 8)
Gastroenterology Insights     Open Access   (Followers: 4)
Gastroenterology Report     Open Access   (Followers: 2)
Gastroenterology Research     Open Access   (Followers: 5)
Gastroenterology Research and Practice     Open Access   (Followers: 3)
Gastrointestinal Cancer : Targets and Therapy     Open Access   (Followers: 2)
Gastrointestinal Endoscopy     Hybrid Journal   (Followers: 24)
Gastrointestinal Endoscopy Clinics of North America     Full-text available via subscription   (Followers: 9)
Gastrointestinal Intervention     Full-text available via subscription   (Followers: 1)
Gastrointestinal Tumors     Full-text available via subscription  
GE Portuguese Journal of Gastroenterology     Open Access  
Gut     Full-text available via subscription   (Followers: 160)
Gut Microbes     Full-text available via subscription   (Followers: 8)
Gut Pathogens     Full-text available via subscription   (Followers: 5)
Hemodialysis International     Hybrid Journal   (Followers: 3)
Hepatic Medicine: Evidence and Research     Open Access   (Followers: 4)
Hepatitis B Annual     Open Access   (Followers: 3)
Hepatitis Monthly     Open Access   (Followers: 4)
Hepatitis Research and Treatment     Open Access   (Followers: 6)
Hepatobiliary & Pancreatic Diseases International     Full-text available via subscription  
Hepatology     Hybrid Journal   (Followers: 41)
Hepatology International     Hybrid Journal   (Followers: 6)
Hepatology Research     Hybrid Journal   (Followers: 13)
Hernia     Hybrid Journal   (Followers: 4)
HPB: The official journal of the International Hepato Pancreato Biliary Association     Hybrid Journal   (Followers: 4)
Indian Journal of Gastroenterology     Open Access   (Followers: 2)
Inflammatory Bowel Diseases     Hybrid Journal   (Followers: 44)
Inflammatory Intestinal Diseases     Full-text available via subscription   (Followers: 1)
Info Diabetologie     Full-text available via subscription  
International Journal of Celiac Disease     Open Access   (Followers: 3)
International Journal of Colorectal Disease     Hybrid Journal   (Followers: 10)
International Journal of Hepatology     Open Access   (Followers: 3)
International Journal of Stomatological Research     Open Access  
Journal Africain d'Hépato-Gastroentérologie     Hybrid Journal   (Followers: 2)
Journal of Clinical Gastroenterology     Hybrid Journal   (Followers: 12)
Journal of Coloproctology     Open Access   (Followers: 1)
Journal of Crohn's and Colitis     Hybrid Journal   (Followers: 10)
Journal of Diabetes Research and Clinical Metabolism     Open Access   (Followers: 2)
Journal of Digestive Diseases     Hybrid Journal   (Followers: 4)
Journal of Digestive Endoscopy     Open Access   (Followers: 3)
Journal of Gastroenterology     Hybrid Journal   (Followers: 12)
Journal of Gastroenterology and Hepatology     Hybrid Journal   (Followers: 14)
Journal of Gastroenterology and Hepatology Research     Open Access   (Followers: 5)
Journal of Gastrointestinal Cancer     Hybrid Journal   (Followers: 4)
Journal of Gastrointestinal Oncology     Open Access   (Followers: 1)
Journal of Hepato-Biliary-Pancreatic Sciences     Hybrid Journal   (Followers: 5)
Journal of Hepatology     Hybrid Journal   (Followers: 21)
Journal of Obesity and Metabolic Research     Open Access   (Followers: 4)
Journal of Social Health and Diabetes     Open Access   (Followers: 2)
Journal of Viral Hepatitis     Hybrid Journal   (Followers: 7)
Kidney Disease and Transplantation     Open Access   (Followers: 2)
Kidney International Supplements     Partially Free   (Followers: 3)
Liver Cancer     Full-text available via subscription   (Followers: 1)
Liver International     Hybrid Journal   (Followers: 12)
Liver Transplantation     Hybrid Journal   (Followers: 10)
Methods in Enzymology     Full-text available via subscription   (Followers: 11)
Nature Reviews Gastroenterology & Hepatology     Full-text available via subscription   (Followers: 31)
Nederlands Tijdschrift voor Diabetologie     Hybrid Journal  
Neurogastroenterology & Motility     Hybrid Journal   (Followers: 2)
Nigerian Journal of Gastroenterology and Hepatology     Full-text available via subscription  
Obesity Science & Practice     Open Access  
Oncology, Gastroenterology and Hepatology Reports     Open Access   (Followers: 3)
Open Journal of Gastroenterology     Open Access   (Followers: 4)
Pancreatology     Full-text available via subscription   (Followers: 3)
Revista Brasileira de Coloproctologia     Open Access  
Revista de Gastroenterología de México     Open Access  
Revista de Gastroenterología de México (English Edition)     Open Access  
Revista Española de Enfermedades Digestivas     Open Access   (Followers: 1)
Revue de Stomatologie et de Chirurgie Maxillo-faciale     Full-text available via subscription   (Followers: 1)
Saudi Journal of Gastroenterology     Open Access   (Followers: 3)
Saudi Journal of Obesity     Open Access  
Scandinavian Journal of Gastroenterology     Hybrid Journal   (Followers: 10)
Seminars in Liver Disease     Hybrid Journal   (Followers: 8)
South African Gastroenterology Review     Full-text available via subscription   (Followers: 1)
Techniques in Coloproctology     Hybrid Journal   (Followers: 11)
Techniques in Gastrointestinal Endoscopy     Hybrid Journal   (Followers: 2)
The Lancet Diabetes and Endocrinology     Full-text available via subscription   (Followers: 128)
Therapeutic Advances in Gastroenterology     Hybrid Journal   (Followers: 6)
United European Gastroenterology Journal     Hybrid Journal   (Followers: 3)
Visible Human Journal of Endoscopy     Full-text available via subscription  
Viszeralmedizin     Full-text available via subscription  
World Council of Enterostomal Therapists Journal     Full-text available via subscription  
World Journal of Gastroenterology     Full-text available via subscription   (Followers: 4)
Zeitschrift für Gastroenterologie     Hybrid Journal   (Followers: 5)

           

Journal Cover Gastroenterology Clinics of North America
  [SJR: 1.238]   [H-I: 68]   [8 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 0889-8553
   Published by Elsevier Homepage  [3043 journals]
  • Prebiotics and Inflammatory Bowel Disease
    • Abstract: Publication date: Available online 4 October 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Heather E. Rasmussen, Bruce R. Hamaker
      Teaser Dietary fiber, specifically prebiotics, is the primary source of energy for the gut microbiota and thus has the potential to beneficially modify microbiota composition. Prebiotics have been used in both in vitro studies and with animal models of colitis with largely positive results. Human studies are few and have been conducted with only a few select prebiotics, primarily fructan-containing fibers. Although disease activity and inflammatory markers have improved, more needs to be learned about the specific prebiotic compounds and how they can be used to best improve the gut microbiota to counter changes induced by inflammatory bowel disease.

      PubDate: 2017-10-08T06:27:08Z
       
  • Herbs and Inflammatory Bowel Disease
    • Abstract: Publication date: Available online 3 October 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Gregory M. Sebepos-Rogers, David S. Rampton
      Teaser Although herbal preparations are widely used by patients with inflammatory bowel disease (IBD), evidence for their efficacy is limited and they may not always be safe. Mainly small studies of varying quality have suggested that several herbal preparations could be of benefit in IBD, but larger better-designed trials are needed to establish their place in inducing and maintaining remission. Patients and health care workers need to be made more aware of the limitations and risks of using herbal products for IBD.

      PubDate: 2017-10-08T06:27:08Z
       
  • Vitamins and Minerals in Inflammatory Bowel Disease
    • Abstract: Publication date: Available online 3 October 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Fayez K. Ghishan, Pawel R. Kiela
      Teaser Indiscriminate multivitamin and mineral supplementation is seen as useless and sometimes harmful, and patients with chronic inflammatory bowel disease (IBD) must be monitored for nutritional and metabolic losses. Mechanistic links between vitamin and mineral deficiencies and IBD has been found for some nutrients; normalizing their systemic level is beneficial. Others, like vitamin A, although instinctively desirable, had disappointing results. Restoring normal levels of selected vitamins and minerals requires elevated doses to compensate for defects in absorptive mechanisms or signaling pathways. This article describes some aspects of vitamin and mineral deficiencies in IBD and summarizes results of supplementation.

      PubDate: 2017-10-08T06:27:08Z
       
  • Fecal Transplant in Inflammatory Bowel Disease
    • Abstract: Publication date: Available online 3 October 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Alexander S. Browne, Colleen R. Kelly
      Teaser Patients with inflammatory bowel disease (IBD) have differences in their gastrointestinal microbiome compared with healthy individuals, although it is unclear whether this is a cause or consequence of chronic inflammation. There is hope that manipulation of the gut microbiome through fecal microbiota transplant (FMT), commonly used to treat patients with Clostridium difficile infection, may also be an effective therapy in IBD. This article reviews the evidence supporting FMT in IBD, including case reports, case series, and randomized controlled trials. The article also focuses on questions of safety and speculates on the future of this therapy.

      PubDate: 2017-10-08T06:27:08Z
       
  • Massage Acupuncture, Moxibustion, and Other Forms of Complementary and
           Alternative Medicine in Inflammatory Bowel Disease
    • Abstract: Publication date: Available online 3 October 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Daniel J. Stein
      Teaser Complementary and alternative medicine is frequently used by inflammatory bowel disease (IBD) patients; most common are massage, acupuncture, and moxibustion therapy. Massage therapy is poorly studied in IBD patients; therefore, its benefits remain unknown. Acupuncture and moxibustion therapy have been shown to improve inflammation and symptoms in animal and human studies. However, current clinical trials of acupuncture and moxibustion are of insufficient quality to recommend them as alternative therapy. Nonetheless, because these therapies seem generally to be safe, they may have a role as complementary to conventional therapy.

      PubDate: 2017-10-08T06:27:08Z
       
  • The Brain-Gut Axis and Stress in Inflammatory Bowel Disease
    • Abstract: Publication date: Available online 3 October 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Charles N. Bernstein
      Teaser The brain-gut axis serves as a circuit that incorporates the human experience, the state of mind, the gut microbiome, and the immune response that ultimately drives the phenotypic expression of inflammatory bowel disease (IBD). There are several biological pathways through which stress can play a deleterious role, including through increasing intestinal permeability, which can facilitate intestinal translocation of bacteria. Stress has an impact on symptoms in IBD; however, there is limited evidence that stress triggers increased intestinal inflammation. Although attention to stress and psychiatric comorbidity is important in the management of IBD, there are few clinical trials to direct management.

      PubDate: 2017-10-08T06:27:08Z
       
  • Psychological Considerations and Interventions in Inflammatory Bowel
           Disease Patient Care
    • Abstract: Publication date: Available online 3 October 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Tiffany H. Taft, Sarah Ballou, Alyse Bedell, Devin Lincenberg
      Teaser The presence of psychological comorbidities, specifically anxiety and depression, is well documented in inflammatory bowel disease (IBD). The drivers of these conditions typically reflect 4 areas of concern: disease impact, treatment concerns, intimacy, and stigma. Various demographic and disease characteristics increase risk for psychological distress. However, the risk for anxiety and depression is consistent throughout IBD course and is independent of disease activity. Early intervention before psychological distress becomes uncontrolled is ideal, but mental health often is unaddressed during patient visits. Understanding available psychological treatments and establishing referral resources is an important part of the evolution of IBD patient care.

      PubDate: 2017-10-08T06:27:08Z
       
  • Probiotics in Inflammatory Bowel Disease
    • Abstract: Publication date: Available online 3 October 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Bincy P. Abraham, Eamonn M.M. Quigley
      Teaser Evidence indicates that the gut microbiota and/or interactions between the microbiota and the host immune system are involved in the pathogenesis of inflammatory bowel disease (IBD). Strategies that target the microbiota have emerged as potential therapies and, of these, probiotics have gained the greatest attention. Data derived from animal models of IBD have revealed the potential of several bacterial strains to modify the natural history of IBD. However, there has been little indication that probiotics exert any benefit in Crohn disease. More targeted approaches involving live bacteria, genetically modified bacteria, and bacterial products are now being evaluated.

      PubDate: 2017-10-08T06:27:08Z
       
  • Mindfulness-Based Interventions in Inflammatory Bowel Disease
    • Abstract: Publication date: Available online 3 October 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Megan M. Hood, Sharon Jedel
      Teaser Mindfulness-based interventions may be beneficial psychosocial treatments for improving the health and well-being of patients with inflammatory bowel disease. This article reviews eight studies, assessing seven psychosocial interventions, which include mindfulness and/or meditation components. Strongest effects of the interventions were found in quality of life and anxiety/depression, with inconsistent or minimal changes in other psychosocial areas, such as perceived stress and in disease-related outcomes and other physiologic functioning. Mindfulness interventions for patients with inflammatory bowel disease may be a supplemental treatment option to improve quality of life and distress in this population, although results are preliminary and interventions require additional testing.

      PubDate: 2017-10-08T06:27:08Z
       
  • Dietary Therapies in Pediatric Inflammatory Bowel Disease
    • Abstract: Publication date: Available online 3 October 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Erin R. Lane, Dale Lee, David L. Suskind
      Teaser Nutrition has long been recognized as a critical component in the treatment of pediatric inflammatory bowel disease (IBD). Formerly, nutritional interventions have focused on targeting improved weight gain and linear growth, as well as correction of micronutrient deficiencies. Recently, there has been growing interest and study of dietary interventions for induction and maintenance of remission. In addition to exclusive enteral nutrition, successes have been achieved with specific exclusion diets. This article evaluates current literature regarding the role of diet and nutrition in pathogenesis of disease, as well as the role of diet as primary therapy for pediatric IBD.

      PubDate: 2017-10-08T06:27:08Z
       
  • Crohn's Disease
    • Abstract: Publication date: September 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 3
      Author(s): Edward V. Loftus


      PubDate: 2017-08-27T15:44:34Z
       
  • Forthcoming Issues
    • Abstract: Publication date: September 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 3


      PubDate: 2017-08-27T15:44:34Z
       
  • Crohn's Disease: Etiology, Complications, Assessment, Therapy, and
           Management
    • Abstract: Publication date: September 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 3
      Author(s): Edward V. Loftus


      PubDate: 2017-08-27T15:44:34Z
       
  • Endoscopic and Radiographic Assessment of Crohn's Disease
    • Abstract: Publication date: September 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 3
      Author(s): Badr Al-Bawardy, Stephanie L. Hansel, Jeff L. Fidler, John M. Barlow, David H. Bruining
      Teaser Crohn’s disease is a chronic inflammatory disorder that can progress to obstructive and penetrating complications. Although clinical symptoms are an important component of therapy, they correlate poorly with objective measures of inflammation. The treatment targets have evolved from clinical improvement only to the addition of more objective measures, such as endoscopic mucosal healing and radiologic response, which have been associated with favorable long-term outcomes, including reduced hospitalizations, surgeries, and need for corticosteroids. There are multiple endoscopic and radiologic scoring systems that can aid in quantifying disease activity and response to therapy. These modalities and scoring tools are discussed in this article.

      PubDate: 2017-08-27T15:44:34Z
       
  • Intestinal and Nonintestinal Cancer Risks for Patients with Crohn's
           Disease
    • Abstract: Publication date: September 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 3
      Author(s): Sushil K. Garg, Fernando S. Velayos, John B. Kisiel
      Teaser Crohn’s disease (CD) is a chronic inflammatory disease that confers a higher risk of cancer than in the general population. New, large, population-based studies in the past decade show that patients with CD are at higher risk of colorectal, small bowel, melanoma, and cervical cancer. Patients who use thiopurines are at additional risk of development of lymphoma and nonmelanoma skin cancer. Preventive surveillance for cancers of the colorectum, skin, and uterine cervix is advised.

      PubDate: 2017-08-27T15:44:34Z
       
  • Interdisciplinary Management of Perianal Crohn's Disease
    • Abstract: Publication date: September 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 3
      Author(s): Amy L. Lightner, William A. Faubion, Joel G. Fletcher
      Teaser Perianal disease is a common manifestation of Crohn disease (CD) that results in significant morbidity and decreased quality of life. Despite several medical and surgical options, complex perianal CD remains difficult to treat. Before the advent of biologic therapy, antibiotics were the mainstay of medical treatment. Infliximab remains the most well-studied medical therapy for perianal disease. Surgical interventions are limited by the risk of nonhealing wounds and potential incontinence. When treatment options fail, fecal diversion or proctectomy may be necessary. Stem cell therapies may offer improved results and seem to be safe, but are not yet widely used.

      PubDate: 2017-08-27T15:44:34Z
       
  • Management of Crohn's Disease After Surgical Resection
    • Abstract: Publication date: September 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 3
      Author(s): Siddharth Singh, Geoffrey C. Nguyen
      Teaser Approximately 25% to 35% of patients with Crohn’s disease (CD) who undergo surgery require repeat surgery. Active smoking, multiple prior surgeries, and penetrating or perianal disease are risk factors for recurrence of CD after surgical resection. Early initiation of prophylactic therapy is effective in decreasing the risk of recurrence. Active colonoscopic surveillance for the early detection of endoscopic recurrence within 6 to 12 months of surgery is recommended. In symptomatic patients without evidence of endoscopic recurrence, noninflammatory causes should be sought.

      PubDate: 2017-08-27T15:44:34Z
       
  • Use of Anti–Tumor Necrosis Factors and Anti-Integrins in the
           Treatment of Crohn's Disease
    • Abstract: Publication date: September 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 3
      Author(s): Raina Shivashankar, Darrell S. Pardi
      Teaser In patients with Crohn’s disease (CD), anti–tumor necrosis factor (TNF) therapy is efficacious for the induction and maintenance of clinical remission, mucosal healing, reducing rates of surgery and hospitalizations, and improving health-related quality of life. The decision between anti-TNFs and anti-integrins as first-line treatment in CD depends on disease severity, safety concerns, and prescription coverage. Given the existing data on long-term outcomes and safety, anti-TNFs are often preferred to anti-integrins. Additional clinical experience and preferably prospective, head-to-head studies will be important to determine whether vedolizumab should be considered more often for first-line therapy in CD.

      PubDate: 2017-08-27T15:44:34Z
       
  • Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease
    • Abstract: Publication date: September 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 3
      Author(s): Parakkal Deepak, William J. Sandborn
      Teaser This article reviews the available data regarding the efficacy of ustekinumab across published randomized clinical trials and open-label experience from tertiary medical centers, safety data, including in pregnancy, and its use in patients who have failed tumor necrosis factor (TNF) antagonists as well as patients who have not failed TNF antagonists. We have proposed an algorithm for positioning the use of ustekinumab among other agents (TNF antagonists, vedolizumab) in moderate-severe Crohn’s disease. The article also enumerates drugs that are specific interleukin-23 blockers, including brazikumab (MEDI2070), risankizumab, LY3074828, tildrakizumab, and guselkumab, and the current status of their clinical trials.

      PubDate: 2017-08-27T15:44:34Z
       
  • Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment
           of Crohn's Disease
    • Abstract: Publication date: September 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 3
      Author(s): Brigid S. Boland, Séverine Vermeire
      Teaser There is an ongoing, unmet need for effective therapies for Crohn’s disease. Treatments for Crohn’s disease continue to evolve from the traditional biologics to novel small molecules, with targeted mechanisms directed toward pathways that are dysregulated in Crohn’s disease. There are multiple emerging mechanisms of action, including Janus kinase inhibition, Smad7 inhibition, and sphingosine-1-phosphate receptor modulators, that are administered as oral medications, and small molecules represent the next generation of therapies for Crohn’s disease.

      PubDate: 2017-08-27T15:44:34Z
       
  • Update on Therapeutic Drug Monitoring in Crohn's Disease
    • Abstract: Publication date: September 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 3
      Author(s): Valérie Heron, Waqqas Afif
      Teaser In patients with Crohn’s disease on biologic medications, the use of therapeutic drug monitoring leads to a personalized approach to optimize treatment. Using an algorithmic approach, measurement of drug concentrations and anti–drug antibodies can be used to improve treatment outcomes. Therapeutic drug concentrations and absence of antibodies are associated with improved clinical and endoscopic outcomes. In clinical practice, therapeutic drug monitoring has been shown to be clinically useful and cost-effective in patients experiencing a loss of response to treatment. This review highlights the available data on therapeutic drug monitoring in the treatment of patients with Crohn’s disease on biologic medications.

      PubDate: 2017-08-27T15:44:34Z
       
  • The Evolution of Treatment Paradigms in Crohn's Disease
    • Abstract: Publication date: September 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 3
      Author(s): Reena Khanna, Vipul Jairath, Brian G. Feagan
      Teaser Despite advances in care, most patients with Crohn’s disease (CD) develop complications, such as fistulas, or require surgery. Given the recent advances in drug therapy, an opportunity exists to optimize the management of this chronic disease through early use of effective therapies, clear definition of treatment targets, and application of the principles of personalized medicine. In this article, the authors discuss the evolution of treatment algorithms for CD to incorporate these strategies.

      PubDate: 2017-08-27T15:44:34Z
       
  • The Microbiome in Crohn's Disease
    • Abstract: Publication date: Available online 19 July 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Sahil Khanna, Laura E. Raffals
      Teaser Individuals with a genetic predisposition to Crohn disease develop aberrant immune responses to environmental triggers. The gastrointestinal microbiota is increasingly recognized to play an important role in the development of Crohn disease. Decrease in global gut microbial diversity and specific bacterial alterations have been implicated in Crohn disease. Advances in sequencing techniques and bioinformatics and correlation with host genetics continue to improve insight into the structure and function of the microbial community and interactions with the host immune system. This article summarizes the existing literature on the role of the gut microbiome and its manipulation in development and management of Crohn disease.

      PubDate: 2017-07-21T08:32:39Z
       
  • Crohn's Disease
    • Abstract: Publication date: Available online 19 July 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Ming-Hsi Wang, Michael F. Picco
      Teaser Since the discovery of the first Crohn’s disease (CD) gene NOD2 in 2001, 140 genetic loci have been found in whites using high-throughput genome-wide association studies. Several genes influence CD subphenotypes and treatment response. With the observations of increasing prevalence in Asia and developing countries and the incomplete explanation of CD variance, other underexplored areas need to be integrated through novel methodologies. Algorithms that incorporate specific genetic risk alleles with other biomarkers will be developed and used to predict CD disease course, complications, and response to specific therapies, allowing precision medicine to become real in CD.

      PubDate: 2017-07-21T08:32:39Z
       
  • Targeting Specific Immunologic Pathways in Crohn's Disease
    • Abstract: Publication date: Available online 19 July 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Guilherme Piovezani Ramos, William A. Faubion, Konstantinos A. Papadakis
      Teaser Understanding the immunologic pathways in intestinal inflammation is crucial for the development of new therapies that can maximize patient response and minimize toxicity. Targeting integrins and cytokines is intended to control leukocyte migration to effector sites or inhibit the action of proinflammatory cytokines. New approaches to preventing leukocyte migration may target integrin receptors expressed on the intestinal vascular endothelium. The IL-12/IL-23 pathway has been a therapeutic target of interest in controlling active Crohn disease (CD). New therapeutic approaches in CD may involve the enhancement of antiinflammatory cytokine pathways, and modulation of cellular responses and intranuclear signals associated with intestinal inflammation.

      PubDate: 2017-07-21T08:32:39Z
       
  • Sexuality, Fertility, and Pregnancy in Crohn's Disease
    • Abstract: Publication date: Available online 19 July 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Jill K.J. Gaidos, Sunanda V. Kane
      Teaser Many factors influence the sexual health of people with Crohn disease but active disease and depression play key roles. The fertility rate in nonoperated patients with inflammatory bowel disease with quiescent disease is similar to the general population. Crohn disease can increase the risk for adverse pregnancy outcomes, but being in remission on a stable, steroid-free medication regimen for at least 3 months before conception and adhering to the treatment throughout pregnancy can improve outcomes. Infants with intrauterine exposure to anti–tumor necrosis factor medications should avoid live vaccines for the first 9 months or until drug concentrations are undetectable.

      PubDate: 2017-07-21T08:32:39Z
       
  • Epidemiology, Natural History, and Risk Stratification of Chron's Disease
    • Abstract: Publication date: Available online 19 July 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Satimai Aniwan, Sang Hyoung Park, Edward V. Loftus
      Teaser Crohn disease (CD) is a chronic condition that can result in significant morbidity and disability. By studying the association between demographics and initial clinical features and subsequent natural history, we may be able to stratify patients by their risks of clinical relapse, hospitalization, and surgery. Understanding the potential environmental risk factors and natural history of CD in a given patient guides the physician when counseling the patient and selecting a treatment strategy. In this review, updated data regarding the incidence and prevalence of CD, important environmental risk factors, natural history of the disease, and important prognostic factors are discussed.

      PubDate: 2017-07-21T08:32:39Z
       
  • Liver Pathology
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2
      Author(s): Jay H. Lefkowitch


      PubDate: 2017-05-18T01:47:40Z
       
  • Forthcoming Issues
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2


      PubDate: 2017-05-18T01:47:40Z
       
  • Erratum
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2


      PubDate: 2017-05-18T01:47:40Z
       
  • IgG4-related Disease and the Liver
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2
      Author(s): Jonathan H. Chen, Vikram Deshpande
      Teaser Pathologists are likely to encounter IgG4-related disease in several organ systems. This article focuses on helping pathologists diagnose IgG4-related disease in the hepatobiliary system. Missing the diagnosis can result in unnecessary organ damage and/or unnecessary surgical and cancer therapy. In the liver, tumefactive lesion(s) involving the bile ducts with storiform fibrosis and an IgG4-enriched lymphoplasmacytic infiltrate are highly concerning for IgG4-related disease. The recent identification of oligoclonal populations of T cells and B cells in IgG4-related disease may lead to molecular tests, new therapeutics, and a greater mechanistic understanding of the disease.

      PubDate: 2017-05-18T01:47:40Z
       
  • Current Concepts in Pediatric Nonalcoholic Fatty Liver Disease
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2
      Author(s): Sarah E. Fleet, Jay H. Lefkowitch, Joel E. Lavine
      Teaser Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of disease. Its increasing prevalence is a direct result of historically high rates of obesity. Hepatocyte lipid accumulation is the first step in a cascade of metabolic and inflammatory events thought to precipitate NAFLD. Histologic findings provide insight into these events. Lifestyle modification remains the primary therapy in children. Current recommendations include vitamin E treatment in those with biopsy-proven NASH. Trials of novel drugs are ongoing in adults. As efficacy/safety are established, these therapies may be tenable for use in children. At the current time, biopsy-driven histology endpoints are necessary to establish whether future therapies can improve pediatric or adult-type NASH in children.

      PubDate: 2017-05-18T01:47:40Z
       
  • Contemporary Evaluation of the Pediatric Liver Biopsy
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2
      Author(s): Deborah A. Schady, Milton J. Finegold
      Teaser Liver disease in the neonate, infant, child, and adolescent may manifest differently depending on the type of disorder. These disorders show marked overlap clinically and on light microscopy. Histology and ultrastructural examination are used in tandem for the diagnosis of most disorders. A final diagnosis or interpretation of the pediatric liver biopsy depends on appropriate and adequate clinical history, laboratory test results, biochemical assays, and molecular analyses, as indicated by the light microscopic and ultrastructural examination.

      PubDate: 2017-05-18T01:47:40Z
       
  • Hepatocellular Adenomas
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2
      Author(s): Paulette Bioulac-Sage, Christine Sempoux, Charles Balabaud
      Teaser Hepatocellular adenomas (HCAs) are rare benign tumors. This single entity has been split into 3 subtypes corresponding to specific mutations: HNF1α-inactivated HCA; inflammatory HCA related to different mutations, all leading to activation of STAT3 pathway; and β-catenin–activated HCA related to CTNNB1 mutations. The risk of malignant transformation depends on the level of β-catenin activation, reported mainly for exon 3, including S45. It is possible using specific immunohistochemical markers to identify the 3 different HCA subtypes and the level of β-catenin activation. Fewer than 10% of HCAs remain unclassified.

      PubDate: 2017-05-18T01:47:40Z
       
  • Drug-induced Liver Injury
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2
      Author(s): David E. Kleiner
      Teaser The evaluation of liver biopsies in suspected drug-induced liver injury (DILI) can be complex. The biopsy may be approached systematically, by identification of histologic lesions and then identification of the overall pattern of injury. Potential DILI must be separated from concomitant non-DILI liver disease. The findings can be analyzed with respect to the various prescription and nonprescription medications and dietary supplements under suspicion to provide a complete interpretation of the findings. The pathologic findings, the histologic differential diagnosis, and expert interpretation are part of a complete biopsy assessment and provide information that is of greatest value in patient management.

      PubDate: 2017-05-18T01:47:40Z
       
  • Antibody-Mediated Rejection After Liver Transplant
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2
      Author(s): Michael Lee
      Teaser Antibody-mediated rejection (AMR) in liver transplants is a field in its infancy compared with its allograft cohorts of the kidney and lung. Acute AMR is diagnosed based on specific clinical and histopathologic criteria: serum donor specific antibodies, C4d staining, histopathologic findings on liver biopsy, and exclusion of other entities. In contrast, the histologic features of chronic AMR are not as specific and it is a more challenging diagnosis to make. Treatments of acute and chronic AMR include some combination of steroids, immune-modulating agents, intravenous immunoglobulin, plasmapheresis, and proteasome inhibitors.

      PubDate: 2017-05-18T01:47:40Z
       
  • Immunohistochemistry in the Diagnosis of Hepatocellular Carcinoma
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2
      Author(s): Won-Tak Choi, Sanjay Kakar
      Teaser Hepatocellular carcinoma (HCC) can be difficult to distinguish from its mimics, including metastatic tumor, benign hepatocellular lesion, and high-grade dysplastic nodule, especially when limited biopsy material is available. Hence, the judicious use of immunohistochemical stains is necessary to establish a correct diagnosis. This article describes advantages and disadvantages of immunohistochemical markers that are most commonly used to distinguish between these lesions. Diagnostic workup of malignant liver mass (HCC and its histologic variants vs metastatic tumor) as well as well-differentiated hepatocellular lesion (well-differentiated HCC vs focal nodular hyperplasia vs hepatocellular adenoma) is also discussed.

      PubDate: 2017-05-18T01:47:40Z
       
  • Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Liver
           Pathology
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2
      Author(s): Mark W. Sonderup, Helen Cecilia Wainwright
      Teaser The improvement in antiretroviral therapy has significantly impacted the lives of people living with human immunodeficiency virus (HIV). In high-income countries, HIV deaths are predominated by liver disease consequent to viral hepatitis coinfection, alcohol, and nonalcoholic fatty liver disease. Published liver pathology findings have shifted from being predominated by opportunistic infections to the metabolic effects of HIV and antiretroviral therapy as well as drug-induced liver injuries. Differences remain between high-income and low-income countries, where opportunistic infections and immune reconstitution syndromes, dominate findings.

      PubDate: 2017-05-18T01:47:40Z
       
  • Autoimmune Hepatitis Overlap Syndromes and Liver Pathology
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2
      Author(s): Albert J. Czaja, Herschel A. Carpenter
      Teaser Autoimmune hepatitis (AIH) may have an atypical serum alkaline phosphatase elevation, antimitochondrial antibodies, histologic features of bile duct injury/loss, or cholangiographic findings of focal biliary strictures and dilations. These manifestations characterize the overlap syndromes. Patients can be classified as having AIH with features of primary biliary cholangitis, primary sclerosing cholangitis, or a cholestatic syndrome. The gold standard of diagnosis is clinical judgment. Histologic evaluation is a major diagnostic component. Treatment is based on algorithms; outcomes vary depending on the predominant disease component. Combination therapy has been the principal recommendation.

      PubDate: 2017-05-18T01:47:40Z
       
  • Morphologic Subtypes of Hepatocellular Carcinoma
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2
      Author(s): Michael S. Torbenson
      Teaser Hepatocellular carcinomas can be further divided into distinct subtypes that provide important clinical information and biological insights. These subtypes are distinct from growth patterns and are on based on morphologic and molecular findings. There are 12 reasonably well-defined subtypes as well as 6 provisional subtypes, together making up 35% of all hepatocellular carcinomas. These subtypes are discussed, with an emphasis on their definitions and the key morphologic findings.

      PubDate: 2017-05-18T01:47:40Z
       
  • Hepatitis E Virus and the Liver
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2
      Author(s): Daniela Lenggenhager, Achim Weber
      Teaser Infection with hepatitis E virus (HEV) is a leading cause of acute hepatitis worldwide, now increasingly recognized also in nonendemic regions. Clinical manifestation of hepatitis E includes mostly asymptomatic/subclinical presentations or acute, self-limiting hepatitis, but also potentially fatal liver failure or chronic hepatitis in immunocompromised individuals. Accordingly, hepatitis E histolpathologic patterns range from an unremarkable histology over acute (cholestatic) hepatitis with variable degree of necrosis to chronic hepatitis with fibrosis. Awareness of hepatitis E and its differential diagnoses, knowledge of its clinico-pathologic manifestations and familiarity with its diagnostic tools will enable clinicians and pathologists to competently make this diagnosis.

      PubDate: 2017-05-18T01:47:40Z
       
  • Hepatic Progenitor Cells
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2
      Author(s): Matthias Van Haele, Tania Roskams
      Teaser Liver regeneration is a fascinating and complex process with many medical implications. An important component of this regenerative process is the hepatic progenitor cell (HPC). These appealing cells are able to participate in the renewal of hepatocytes and cholangiocytes when the normal homeostatic regeneration is exhausted. Moreover, the HPC niche is of vital importance toward the activation, differentiation, and proliferation of the HPC. This niche provides a rich microenvironment for the regulation of the HPC, thanks to the intercellular secretion of molecules. New findings indicate that the regenerative possibilities in the liver could provide a diverse basis for therapeutic targets.

      PubDate: 2017-05-18T01:47:40Z
       
  • Heart Disease and the Liver
    • Abstract: Publication date: June 2017
      Source:Gastroenterology Clinics of North America, Volume 46, Issue 2
      Author(s): Anne Knoll Koehne de Gonzalez, Jay H. Lefkowitch
      Teaser Liver injury due to acute and chronic heart failure has long been recognized. This article discusses the concepts of acute cardiogenic liver injury (ACLI) and cardiac or congestive hepatopathy (CH) along with their clinical manifestations and sequelae. Histologically, ACLI manifests as centrilobular hepatocellular necrosis, whereas CH is associated with centrilobular hepatocyte atrophy, dilated sinusoids, and perisinusoidal fibrosis, progressing to bridging fibrosis and ultimately cirrhosis. ACLI is associated with marked increases in aminotransferase levels, whereas CH is associated with a cholestatic pattern of laboratory tests. Certain cardiac medications have also been implicated as a cause of liver fibrosis.

      PubDate: 2017-05-18T01:47:40Z
       
  • Liver Pathology
    • Abstract: Publication date: Available online 14 April 2017
      Source:Gastroenterology Clinics of North America
      Author(s): Jay H. Lefkowitch


      PubDate: 2017-04-18T21:58:57Z
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.166.203.76
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016